文献速递儿童青少年精神心境障碍精神分裂症与精神病性障碍

注意缺陷多动障碍患者兴奋剂治疗结局的遗传、临床与社会人口学因素

Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD.
PubMed 文献 · Am J Psychiatry · 2021-06-22

该研究基于丹麦iPSYCH2012样本中9133例ADHD个体的遗传与登记数据,分析兴奋剂治疗启动、停用及换用非兴奋剂的相关因素。结果显示,心境与精神病性障碍多基因风险、较晚诊断及精神共病与更高的停用和换药风险相关,未发现显著SNP遗传度或启动/停用的全基因组关联位点。

要点

  • 双相障碍与精神分裂症多基因风险评分与兴奋剂停用风险轻度升高相关。
  • 13岁及以上才诊断ADHD者兴奋剂启动、停用及换药率均更高。
  • 精神共病通常降低启动率并增加停用及换药率。

核心结论

  • ADHD个体若对心境和/或精神病性障碍多基因易感性更高、诊断延迟或存在精神共病,兴奋剂停用及换用非兴奋剂的风险更高。

研究设计与样本

  • 研究纳入丹麦iPSYCH2012样本中9133例ADHD个体,获取遗传与国家登记数据,定义兴奋剂治疗启动、停用和换药。
  • 采用生存分析检验多基因风险评分(PRS)、临床及社会人口学因素与各治疗结局的关联,并进行全基因组关联研究(GWAS)和估计单核苷酸多态性遗传度(h2SNP)。

主要发现

  • 双相障碍PRS(风险比=1.05,95%CI=1.02,1.09)和精神分裂症PRS(风险比=1.07,95%CI=1.03,1.11)与停用相关。
  • 抑郁、双相障碍和精神分裂症PRS与换药呈边缘性但非显著关联(风险比范围1.05-1.07)。
  • ADHD和孤独症PRS未观察到关联;h2SNP估计与零无显著差异;启动或停用未发现GWAS显著位点。
  • 13岁及以上诊断ADHD者启动、停用和换药率更高(风险比范围1.27-2.01);精神共病降低启动率(风险比范围0.84-0.88)并增加停用率(风险比范围1.19-1.45)和换药率(风险比范围1.40-2.08)。

关键数值与推荐

  • 换药在全基因组显著水平上发现染色体16q23.3一个位点。

临床怎么用

  • 对ADHD患者处方兴奋剂时,可关注其心境/精神病性障碍多基因负荷、诊断年龄及精神共病,以识别停用或换药风险较高者。

局限性

  • 研究样本量有限,仅识别出一个可能的换药GWAS位点,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stimulant medications are effective for treating attention deficit hyperactivity disorder (ADHD), yet discontinuation and switch to nonstimulant ADHD medications are common. This study aimed to identify genetic, clinical, and sociodemographic factors influencing stimulant treatment initiation, discontinuation, and switch to nonstimulants in individuals with ADHD. METHODS: The authors obtained genetic and national register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample and defined stimulant treatment initiation, discontinuation, and switch from prescriptions. For each stimulant treatment outcome, they examined associations with polygenic risk scores (PRSs) for psychiatric disorders and clinical and sociodemographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated single-nucleotide polymorphism heritability (h2SNP). RESULTS: Eighty-one percent of the sample initiated stimulant treatment. Within 2 years, 45% discontinued stimulants and 15% switched to nonstimulants. Bipolar disorder PRS (hazard ratio=1.05, 95% CI=1.02, 1.09) and schizophrenia PRS (hazard ratio=1.07, 95% CI=1.03, 1.11) were associated with discontinuation. Depression, bipolar disorder, and schizophrenia PRSs were marginally but not significantly associated with switch (hazard ratio range, 1.05-1.07). No associations were observed for ADHD and autism PRSs. Individuals diagnosed with ADHD at age 13 or older had higher rates of stimulant initiation, discontinuation, and switch (hazard ratio range, 1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (hazard ratio range, 0.84-0.88) and increased rates of discontinuation (hazard ratio range, 1.19-1.45) and switch (hazard ratio range, 1.40-2.08). h2SNP estimates were not significantly different from zero. No GWAS hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch. CONCLUSIONS: The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brikell I, Wimberley T, Albiñana C, et al. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. Am J Psychiatry. 2021. PMID: 34154395. doi:10.1176/appi.ajp.2020.20121686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。